New drugs in gynecologic cancer
- PMID: 12057130
- DOI: 10.1007/s11864-001-0054-0
New drugs in gynecologic cancer
Abstract
The implementation of new drug treatments has improved the prognosis for advanced cancers of the cervix, uterus, and ovary. Platinum analogs are the most effective drugs in the treatment of ovarian cancer. Other drugs, such as oxaliplatin, have been proposed as a rational treatment of platinum refractory ovarian cancer. Epothilones are also being studied in clinical trials, as are histone deacetylase inhibitors. Several promising agents may soon receive Food and Drug Administration approval.
Similar articles
-
New oxaliplatin-based combinations in the treatment of colorectal cancer.Colorectal Dis. 2003 Nov;5 Suppl 3:1-9. doi: 10.1046/j.1463-1318.5.s3.2.x. Colorectal Dis. 2003. PMID: 23573555 Review.
-
Novel molecular targeted therapies for refractory thyroid cancer.Head Neck. 2012 May;34(5):736-45. doi: 10.1002/hed.21755. Epub 2011 May 4. Head Neck. 2012. PMID: 21544895 Review.
-
Targeted therapies in gynecologic cancers.Curr Cancer Drug Targets. 2006 Jun;6(4):333-63. doi: 10.2174/156800906777441799. Curr Cancer Drug Targets. 2006. PMID: 16848724 Review.
-
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.Curr Cancer Drug Targets. 2006 Jun;6(4):271-94. doi: 10.2174/156800906777441780. Curr Cancer Drug Targets. 2006. PMID: 16848720 Review.
-
[Promising targeted molecular therapies for the future years in non-small-cell lung cancer].Rev Pneumol Clin. 2006 Feb;62 Spec no 1:1S35-6. Rev Pneumol Clin. 2006. PMID: 16719155 French. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources